Charles River Laboratories Intl. Inc vs Vanguard High Dividend Yield ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $286.53 (market cap $13.46B), while Vanguard High Dividend Yield ETF trades at $166.76. Which is the better fit depends on your goals.
| CRL | VYM | |
|---|---|---|
Market Cap | $13.46B | — |
Sector | Health | — |
52-Week High | $282.00 | $166.14 |
52-Week Low | $145.57 | $136.63 |
Enterprise Value | $16.30B | — |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
VYM trades at $166.51, up 0.27% with a bullish technical signal from moving averages but overbought RSI readings. The ETF recently hit a new 52-week high and maintains strong institutional interest despite some position reductions. Recent news highlights VYM's role in retirement income strategies with a 2.2% dividend yield and decade-long performance comparisons to the S&P 500.
The outlook remains positive for income-focused investors given VYM's sustainable dividend growth and sector diversification. Key risks include potential underperformance versus growth indices and sensitivity to interest rate changes. Wall Street sentiment is generally favorable with the ETF positioned as a core holding for retirement portfolios.
Trailing returns across standard periods
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →